<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605383</url>
  </required_header>
  <id_info>
    <org_study_id>XCEL-MT-10-01</org_study_id>
    <secondary_id>2010-023998-18</secondary_id>
    <nct_id>NCT01605383</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head</brief_title>
  <official_title>A Pilot Clinical Trial of &quot;ex Vivo&quot; Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue (XCEL-MT-OSTEO- ALPHA) in Osteonecrosis of the Femoral Head</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Sanidad, Servicios Sociales e Igualdad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Ciencia e Innovación, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Regional Development Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study evaluates the effect of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral
      head in comparison to the standard treatment of isolated core decompression.

      XCEL-MT-OSTEO-ALPHA is a tissue engineering product composed by &quot;ex-vivo&quot; expanded autologous
      mesenchymal stem cells fixed in allogenic bone tissue.

      The working hypothesis proposes that the tissue engineering is a valid and useful technique
      to achieve bone regeneration, avoiding the progression to collapse of the femoral head.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, open-label with blinded assessor, randomized, parallel, single-dose phase I-II
      clinical trial in which 24 patients affected with osteonecrosis of the femoral head ARCO
      grade I or II will enter the trial with the primary objective of assessing the feasibility
      and safety of &quot;ex-vivo&quot; expanded autologous mesenchymal stem cells fixed in allogenic bone
      tissue in osteonecrosis of the femoral head. Secondary objectives are to assess the efficacy
      of the implantation by imaging (magnetic resonance imaging) and clinical questionnaires (pain
      by visual analogue scale, quality of life by SF-36 and WOMAC Index).

      Patients will be randomized to one of the two treatment arms (core decompression and the
      tissue engineering product composed by &quot;ex-vivo&quot; expanded autologous mesenchymal stem cells
      fixed in allogenic bone tissue or the standard treatment of isolated core decompression).
      Thereafter, patients will be followed for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head</measure>
    <time_frame>12 months</time_frame>
    <description>Safety will be assessed by collecting adverse events throughout the experimental phase, which includes a follow-up of 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head</measure>
    <time_frame>12 months</time_frame>
    <description>Feasibility will be measured by assessing the percentage of patients to which bone marrow puncture is made are thereafter treated and by checking the cascade of procedures to confirm the global process is viable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone regeneration by measuring the necrotic angle using the modified Kerboul method</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>The necrotic angle will be measured using imaging procedures (magnetic resonance imaging MRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of signal intensity</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Dynamic changes of signal intensity after Gd enhancement in the necrotic areas of the femoral head</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes (pain) by Visual Analogue Scale (VAS)</measure>
    <time_frame>7 days and at 3, 6 and 12 months</time_frame>
    <description>Pain measurement by VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes (SF-36)</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>This clinical outcome will measure the quality of life by the self-reported quality of life questionnaire SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome (WOMAC)</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>To assess the extent by which a person's functional level is restricted by the WOMAC index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Avascular Necrosis of Femur Head</condition>
  <arm_group>
    <arm_group_label>XCEL-MT-OSTEO-ALPHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;ex-vivo&quot; expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Isolated core decompression</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XCEL-MT-OSTEO-ALPHA</intervention_name>
    <description>Core decompression plus XCEL-MT-OSTEO-ALPHA</description>
    <arm_group_label>XCEL-MT-OSTEO-ALPHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Isolated core decompression</description>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 50 years of age (male and female)

          -  Osteonecrosis of the hip ARCO grade I or II

          -  Abscence of systemic or local infection

          -  Laboratory tests with no relevant abnormal findings that contraindicate the surgery.

          -  Informed Consent Form signed

          -  The patient is able to understand the nature of the study

        Exclusion Criteria:

          -  Osteonecrosis of the hip secondary to femoral neck fracture

          -  Patients with no closed cartilage

          -  Surgical implants in the femoral head

          -  Septic arthritis

          -  Patients with severe renal insufficiency

          -  Patients expecting or with liver transplantation

          -  Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab)
             or Syphilis.

          -  Pregnant woman or intended to become pregnant, or breath feeding

          -  Neoplasia within the previous 5 years, or without remission

          -  Immunosuppressive states

          -  The patient is legally dependent

          -  Participation in another clinical trial or treated with an investigational medicinal
             product the previous 30 days

          -  Cardiac pacemaker, allergy to contrast or any other condition that contraindicates the
             MRI with contrast agents

          -  Other pathologic conditions or circumstances that difficult participation in the study
             according to medical criteria

          -  The patient does not accept to be followed-up for a period thar could exceed the
             clinical trial length
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Màrius Aguirre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bancsang.net/</url>
    <description>Banc de Sang i Teixits. Xcelia-División de Terapias Avanzadas.</description>
  </link>
  <link>
    <url>http://www.vhebron.net/</url>
    <description>Hospital Universitari Vall d'Hebron, Barcelona</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avascular Necrosis of Femur Head</keyword>
  <keyword>Osteonecrosis of the hip</keyword>
  <keyword>Osteonecrosis of the femoral head</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Tissue engineering</keyword>
  <keyword>Bone Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Osteonecrosis</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

